Table 1. Clinical information of the eligible trials for the meta-analysis.
| Trial reference | Tumor characteristics WHO grade | Clinical trial phase | Patients (male) and control | Median age | Pre- Therapy KPS | Previous treatment | DC Arm Injection | DC regimens | Culture of DC cells |
| Chen-Nen Chang2011[17] | New or Recurrent III/IV | I/II | 17(8); 63(UK); historical | 44.7; UK | Median; 90 | CT/RT | DCs loaded with AIT (s.c) | 1.0–6.1×107/course | GM-CSF, IL-4 |
| Ryuya Yamanaka 2005[18] | RecurrentIII/IV | I/II | 24(16); 27(UK); historical | 48.9; 55.9 | Median; 62.5 | SR/RT, CT | DCs loaded with ATL (i.d or i.t) | 3.9–240.9×106/course | GM-CSF, IL-4, KLH |
| Christopher J Wheeler 2004[19] | De novo IV | I/II | 25(11); 25(13); randomized | 55; 50 | >60 | SR/CT, RT | DCs loaded with ATL or HLP | 10–40 ×106/course | UK |
| Linda M.Liau 2005[20] | New or Recurrent IV | I | 12(5); 99(UK); historical | 40.4; <50 | ≥60 | CT/ICH | DCs loaded with ATP | 1–10×106/course | GM-CSF, IL-4 |
| Tetsuro Kikuchi 2001[21] | Recurrent UK | I | 8(7) | 38 | Median 70 | SR/CT, RT | DCs fused with AIT (i.d) | 2.4–8.7×106/course | GM-CSF, IL-4,TNF-α |
| R Yamanaka 2003[22] | Recurrent UK | I/II | 10(4) | 46 | Median 54 | SR/RT | DCs loaded with ATL (i.d) | 10–137.2×106/course | GM-CSF, IL-4, KLH |
| John S. Yu 2004[23] | New or Recurrent UK | I | 14(10); 26(UK); historical | 45; 53 | ≥60 | SR/CT | DCs loaded with ATL (i.d) | 107–108/course | GM-CSF, IL-4 |
| X.Jie 2012[24] | Recurrent IV | I/II | 13(10); 12(9); randomized | 40.2; 43.1 | ≥60 | SR/RT, CT | DCs loaded with AHT and GM-CSF(s.c) | 6×106/course | GM-CSF, IL-4, IL-1β, PGE2, TNF-α |
| Der-Yang Cho 2011[25] | New IV | II | 18(8); 16(8); randomized | 58.6; 55.8 | >70 | SR/CT, RT | DCs loaded with ATL(s.c) | 2–5×107/course | GM-CSF, IL-4 |
The table summarizes the patients' basic information about the tumor stage, newly or recurrent, cases, age, KPS, operative method before the immunotherapy and details of the immunotherapy including the DC, tumor antigen, and loading route. The last row is the culture conditions used for the cells. KPS: Karnofsky performance status; AIT: Autologous irradiated tumor cells; ATL: Autologous tumor lysate; HLP: HLA-1-eluted peptides; ATP: Autologous acid-eluted tumor peptides; AHT: Autologous heat-shock tumor cells; CT: Chemical therapy; RT: Radiation therapy; SR: Surgical resection; KLH: Keyhole limpet hemocyanin; PGE2: Prostaglandin E2; TNF-α: Tumor necrosis factor-α; IL-4: Interleukin-4; i.d.: intradermalvaccination; i.t.: intratumoral vaccination; s.c.:subcutaneous injection; ICH: intra-cellular hyperthermia; UK: Unknown.